These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 23713868)
1. Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation. Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Oliveira HF; Scrideli CA; Tone LG Cancer Biother Radiopharm; 2013 Sep; 28(7):516-22. PubMed ID: 23713868 [TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968 [TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645 [TBL] [Abstract][Full Text] [Related]
5. PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs. Brassesco MS; Pezuk JA; Salomão KB; Roberto GM; Scrideli CA; Tone LG Anticancer Agents Med Chem; 2018; 18(9):1252-1257. PubMed ID: 29493466 [TBL] [Abstract][Full Text] [Related]
6. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. Danovi D; Folarin A; Gogolok S; Ender C; Elbatsh AM; Engström PG; Stricker SH; Gagrica S; Georgian A; Yu D; U KP; Harvey KJ; Ferretti P; Paddison PJ; Preston JE; Abbott NJ; Bertone P; Smith A; Pollard SM PLoS One; 2013; 8(10):e77053. PubMed ID: 24204733 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Krause M; Kummer B; Deparade A; Eicheler W; Pfitzmann D; Yaromina A; Kunz-Schughart LA; Baumann M Radiother Oncol; 2013 Sep; 108(3):422-8. PubMed ID: 23891096 [TBL] [Abstract][Full Text] [Related]
10. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Stehle A; Hugle M; Fulda S Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079 [TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629 [TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839 [TBL] [Abstract][Full Text] [Related]
14. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase. Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893 [TBL] [Abstract][Full Text] [Related]
15. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800 [TBL] [Abstract][Full Text] [Related]
16. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758 [TBL] [Abstract][Full Text] [Related]
17. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells. Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075 [TBL] [Abstract][Full Text] [Related]
18. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
19. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments. Bogado RF; Pezuk JA; de Oliveira HF; Tone LG; Brassesco MS Anticancer Drugs; 2015 Jan; 26(1):56-63. PubMed ID: 25089571 [TBL] [Abstract][Full Text] [Related]
20. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Hu K; Law JH; Fotovati A; Dunn SE Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]